Tech Company Financing Transactions
Zyngenia Funding Round
Zyngenia closed a $15 million Series A venture capital round on 9/8/2010. Investors included New Enterprise Associates.
Transaction Overview
Company Name
Announced On
9/8/2010
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
New Enterprise Associates (David Mott)
Proceeds Purpose
The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1050 Connecticut Ave. NW 500
Washington, DC 20036
USA
Washington, DC 20036
USA
Phone
Website
Email Address
Overview
At Zyngenia, we are developing the next generation of antibody-based drugs called Zybody therapeutics. We are spearheading the development of this novel class of drugs to create more potent and more broadly acting protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Parkinson
Chief Scientific Officer
David Hilbert
Vice President
Viktor Roschke
Browse more venture capital transactions:
Prev: 9/8/2010: ByAllAccounts venture capital transaction
Next: 9/9/2010: ioSemantics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs